Absci Corporation, a clinical-stage biopharmaceutical company, has announced the commencement of its first clinical trial for ABS-101, an AI-designed biologic aimed at treating inflammatory bowel disease $(IBD)$. The Phase 1 trial is currently underway with the first healthy volunteers dosed in a randomized, placebo-controlled study. ABS-101, engineered using Absci's generative AI platform, boasts superior potency and reduced immunogenicity, offering potential improvements in efficacy and patient convenience with quarterly dosing. Interim data from this trial is anticipated in the second half of 2025. Additionally, Absci is advancing ABS-201, an AI-designed anti-prolactin receptor antibody for treating androgenetic alopecia, with preclinical data showing promising results. The Phase 1 trials for ABS-201 are expected to commence in early 2026.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。